Michael T. Schweizer

7.0k citations

144 papers · 3.1k indexed · h-index 33

Impact in

Pulmonary and Respiratory Medicine top 1%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Cancer Research top 2%
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics

Papers in

Pulmonary and Respiratory Medicine 113
- Prostate Cancer Treatment and Research 101
- Prostate Cancer Diagnosis and Treatment 17
Cancer Research 31
- Cancer Genomics and Diagnostics 15
- Cancer, Lipids, and Metabolism 15

Co-authors: Emmanuel S. Antonarakis Mario A. Eisenberger Evan Y. Yu Peter S. Nelson Bruce Montgomery Heather H. Cheng Rosa Nadal Colin C. Pritchard
Journals: Journal of Clinical Oncology (45 papers)The Prostate (11 papers)Clinical Cancer Research (7 papers)Annals of Oncology (6 papers)JCO Precision Oncology (6 papers)
Partner nations: United States Spain Germany

In The Last Decade

Michael T. Schweizer

131 papers receiving 3.0k citations

Peers

Countries citing papers authored by Michael T. Schweizer

Since Specialization

Citations

This map shows the geographic impact of Michael T. Schweizer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael T. Schweizer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael T. Schweizer more than expected).

Fields of papers citing papers by Michael T. Schweizer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael T. Schweizer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael T. Schweizer. The network helps show where Michael T. Schweizer may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael T. Schweizer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael T. Schweizer Line = papers co-authored together Michael T. Schweizer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	MEVROMETOSTAT (PF-06821497) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE: THE PHASE 3, RANDOMIZED MEVPRO-1 STUDY Urologic Oncology Seminars and Original Investigations ·Neeraj Agarwal, Michael T. Schweizer, Elena Castro, Arun Azad, Daniel J. George, Jayeta Chakrabarti, Sujata Narayanan, Yiyun Tang, Karim Fizazi	2025	1
2	Molecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosis Histopathology ·J. J. Sloan, Fernanda M Cajú, Michael T. Schweizer, Stephanie A. Harmon, Colm Morrissey, Himisha Beltran, Peter S. Nelson, Liang Cheng, Chien‐Kuang Cornelia Ding, Michael C. Haffner	2025	0
3	2385MO Translational analyses of T cell phenotypes and their association with clinical efficacy in the first-in-human (FIH) trial of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC) Annals of Oncology ·Karen A. Autio, Michael T. Schweizer, G. Kletke, Rajendra Chaudhary, Michael T. Brady, S. Casanova, Patricia M. Raciti, Mark N. Stein, Jihoon Doo	2025	0
4	Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 trial. Journal of Clinical Oncology ·Michael T. Schweizer, Jayeta Chakrabarti, Sujata Narayanan, Reham Ragab	2025	1
5	1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC) Annals of Oncology ·Bibhusal Thapa, 豊富重, A. Béché, Clara Hwang, Alexandra Sokolova, Mehmet Asım Bilen, Manjunath Shankariah, C. Kolmerowa, Archana Tripathi, 宋连, Laura Graham, Yousef Zakharia, 祐二保坂, Elisabeth I. Heath, Tanya B. Dorff, Shou Haiming, Rana R. McKay, Ajjai Alva, Michael T. Schweizer, Deepak Kilari	2024	0
6	Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer Arkadii I Lipkin, Michael T. Schweizer, Jessica E. Hawley, Lawrence Fong, Evan Y. Yu	2024	2
7	Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to ¹⁷⁷Lu-PSMA-617: A Retrospective Multicenter Cohort Study JCO Precision Oncology ·Arkadii I Lipkin, George Mo, Invonne Suryana, Laura Graham, Roman Gulati, Colin C. Pritchard, Michael C. Haffner, Todd Yezefski, Jessica E. Hawley, Heather H. Cheng, Evan Y. Yu, Petros Grivas, Bruce Montgomery, Peter S. Nelson, Delphine L. Chen, Thomas A. Hope, Amir Iravani, Michael T. Schweizer	2024	7
8	Hematologic toxicity in ¹⁷⁷lu-PSMA-617 treatment for mCRPC: Unraveling the impact of PSMA PET bone tumor volume (PSMA-bTTV). Journal of Clinical Oncology ·雅彦中川, Lanczkor Renáta, Roman Gulati, Arkadii I Lipkin, Heather H. Cheng, Jessica E. Hawley, Todd Yezefski, Michael C. Haffner, Bruce Montgomery, Peter S. Nelson, Michael T. Schweizer, Evan Y. Yu, Delphine L. Chen, Amir Iravani	2024	3
9	A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1 Clinical Cancer Research ·Neeraj Agarwal, Daniel Castellano, Teresa Alonso‐Gordoa, Jóse Ángel Arranz Arija, Émeline Colomba, Gwénaëlle Gravis, Loı̈c Mourey, Stéphane Oudard, Aude Fléchon, Alberto Mair, Pablo Maroto, Michael T. Schweizer, Enrique Gallardo, Jianyin ChenLijue XueSheng-Hui Wang, Arjun Vasant Balar, Nadine Haddad, Adams K. Appiah, J. G. Wang, Josep M. Piulats	2024	6
10	Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer The Prostate ·Mark P. Labrecque, Lisha G. Brown, Ilsa M. Coleman, Holly M. Nguyen, Susan L. Dalrymple, W. Nathaniel Brennen, John T. Isaacs, Dapei Li, Bryce Lakely, Johnny Alexander Miramag-Cánchala, John K. Lee, Michael T. Schweizer, Daniel W. Lin, Eva Corey, Peter S. Nelson, Colm Morrissey	2023	4
11	Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer Clinical Genitourinary Cancer ·Emerson A. Lim, Michael T. Schweizer, Kim N., Rahul Aggarwal, Neeraj Agarwal, James L. Gulley, Edward F. Attiyeh, James Greger, Shujian Wu, Sabuori Deilami Mohamad Hasan, John T. Loffredo, Nibedita Bandyopadhyay, Hong Xie, Aaron R. Hansen	2023	32
12	Clinical, pathologic, and molecular features of amphicrine prostate cancer The Prostate ·Laura Graham, Michael C. Haffner, Fernanda M Cajú, Katsunori Mikuniya, Michael T. Schweizer, Colin C. Pritchard, Ilsa M. Coleman, Peter S. Nelson, Evan Y. Yu	2023	7
13	734 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099280, in patients with select advanced solid tumors Regular and Young Investigator Award Abstracts ·Hans Prenen, Thierry Lesimple, Marie E. Robert, Québec . Ministère de la santé et des services sociaux, Jean‐Pascal Machiels, Tarek Meniawy, Eric Van Cutsem, Nuria Kotecki, Sarina A. Piha‐Paul, Michael T. Schweizer, Shirish M. Gadgeel, Carina Patrícia Moreira Azevedo, Louis Viviers, 加絵藤澤, Antoîne Italiano	2022	2
14	Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer Clinical Cancer Research ·Elahe A. Mostaghel, Brett T. Marck, Orpheus Kolokythas, Felix S. Chew, Evan Y. Yu, Michael T. Schweizer, Heather H. Cheng, Philip W. Kantoff, Steven P. Balk, Mary‐Ellen Taplin, Nima Sharifi, Alvin M. Matsumoto, Peter S. Nelson, Bruce Montgomery	2021	17
15	Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade Clinical Cancer Research ·Laura Graham, Colin C. Pritchard, Michael T. Schweizer	2021	13
16	Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer Clinical Cancer Research ·Christos E. Kyriakopoulos, Jens C. Eickhoff, Anna C. Ferrari, Michael T. Schweizer, 马利斯·施维泽Maurice, Brian M. Olson, Douglas G. McNeel	2020	47
17	A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Clinical Cancer Research ·Rahul Aggarwal, Michael T. Schweizer, David M. Nanus, Allan J. Pantuck, Elisabeth I. Heath, Eric Campeau, Sarah Attwell, Karen Norek, A Naftaliev, Lisa Bauman, Sanjay Lakhotia, Felix Y. Feng, Eric J. Small, Wassim Abida, Joshi J. Alumkal	2020	97
18	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies PLoS ONE ·Laura Graham, Bruce Montgomery, Heather H. Cheng, Evan Y. Yu, Peter S. Nelson, Colin C. Pritchard, Liu Wenzhang, Ajjai Alva, Michael T. Schweizer	2020	63
19	Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage Journal of Clinical Investigation ·Payel Chatterjee, Michael T. Schweizer, Jared M. Lucas, Ilsa Coleman, Michael D. Nyquist, Sander B. Frank, Robin Tharakan, Elahe A. Mostaghel, Jun Luo, Colin C. Pritchard, Hung‐Ming Lam, Eva Corey, Emmanuel S. Antonarakis, Samuel R. Denmeade, Peter S. Nelson	2019	67
20	MSH2 Loss in Primary Prostate Cancer Clinical Cancer Research ·Liana B. Guedes, Emmanuel S. Antonarakis, Michael T. Schweizer, Nooshin Mirkheshti, Fawaz Almutairi, Jong Chul Park, Stephanie Glavaris, Jessica Hicks, Mario A. Eisenberger, Angelo M. De Marzo, Jonathan I. Epstein, William B. Isaacs, James R. Eshleman, Colin C. Pritchard, Tamara L. Lotan	2017	112

About Michael T. Schweizer

Michael T. Schweizer is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism, having authored 144 papers that have together received 3.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (101 papers), Radiopharmaceutical Chemistry and Applications (32 papers), Prostate Cancer Diagnosis and Treatment (17 papers), PARP inhibition in cancer therapy (17 papers), Hormonal and reproductive studies (16 papers), Cancer Immunotherapy and Biomarkers (16 papers), Cancer Genomics and Diagnostics (15 papers) and Cancer, Lipids, and Metabolism (15 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.2k citations), Cancer Research (746 citations), Oncology (1.1k citations), Endocrinology, Diabetes and Metabolism (346 citations) and Radiology, Nuclear Medicine and Imaging (444 citations). Michael T. Schweizer has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Emmanuel S. Antonarakis, Mario A. Eisenberger, Evan Y. Yu, Peter S. Nelson, Bruce Montgomery, Heather H. Cheng, Rosa Nadal, Colin C. Pritchard, Michael A. Carducci and Jonathan I. Epstein. Their work appears in journals such as Journal of Clinical Oncology, The Prostate, Clinical Cancer Research, Annals of Oncology and JCO Precision Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact